Malaysia Moves: Asian Medtech Associations Regulatory Networking November 2017, Part I
Executive Summary
The second Asian Medtech Associations Regulatory Networking discussion focused on a range of regional issues, including the latest on-the-ground news and views. Hosted by Medtech Insight, and sponsored by the Asia Regulatory and Quality Consultancy (ARQon), the Asia Regulatory Professionals Association (ARPA) and Medtronic, this session is reported in two parts, with this first part focusing on Malaysia.
You may also be interested in...
Next ASEAN Device Committee Meeting Looms, But National Regs Top Priorities
New medtech regulations in Singapore, a new medtech law in the Philippines, and another deferral of Act 737 in Malaysia were the focus of the Asian Medtech Associations Regulatory Networking discussions this month. In a break from the usual focus, there was also an update on the EU MDR and preparations for Brexit from the UK Association of HealthTech Industries (ABHI). This series is hosted by Medtech Insight and sponsored by the Asia Regulatory and Quality Consultancy (ARQon), and the Asia Regulatory Professionals Association (ARPA).
Malaysia Clarifies Content, Language And Other Labeling Requirements For Devices, IVDs
Manufacturers and authorized representatives operating in Malaysia must not place labels over a device’s lot/batch or serial number, date of manufacturing or date of expiry, says new guidance on how to label products.
Asia Reg Roundup: Vietnam Decree, Malaysia Labels And More
Medtech companies selling into the Vietnam market need to start preparing for major regulatory changes that will be introduced in 2017 via a new decree. That is the advice of Asia Regulatory Professional Association (ARPA) secretary Jack Wong and ARQon consultant May Ng, who spoke to Medtech Insight on a range of regional Asian regulatory issues for this September update.